Physician
Hematology
Dr. Jeffrey J. Molldrem, MD
|
|
Give Review
Jeffrey Molldrem works in the field of Hematology. He went to medical school at University of Minnesota Medical School. University of Minnesota Medical School has a rank of 40 in research and a 10 in primary care He received awards:"Elected Member". Jeffrey J. Molldrem is also a published doctor. He has 97 publication published. The most recent publication is: Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. He accepts all Medicare patients.
Publications
- Enforced fucosylation of cord blood hematopoietic Cells accelerates neutrophil and platelet engraftment after transplantation.
- Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future.
- Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in Chronic GVHD.
- PD-L1 Expression in Triple-Negative Breast Cancer.
- CD13-positive bone marrow-derived Myeloid cells promote angiogenesis, tumor growth, and metastasis.
- Kernel Machine SNP-Set Testing Under Multiple Candidate Kernels.
- Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
- A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in Acute myeloid leukemia.
- Cord-blood engraftment with ex vivo mesenchymal-Cell coculture.
- Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy.
- Breast cancer Cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.
- Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation.
- Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.
- Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem Cell transplantation.
- Targeting human B-Cell malignancies through Ig light chain specific cytotoxic T lymphocytes.
- PMLRAR{alpha} binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.
- An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against Acute myeloid leukemia progenitor cells.
- Common Minor Histocompatibility Antigen Discovery Based upon Patient Clinical Outcomes and Genomic Data.
- Lovastatin inhibits T-Cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.
- 2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1.
- Immune rage against MAGE unleashed.
- Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host Disease.
- Immunotherapy of AML.
- PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous Leukemia after interferon withdrawal.
- Preparing basic and translational grant proposals: thoughts from the trenches.
- Blocking LFA-1 activation with lovastatin prevents graft-versus-host Disease in mouse bone marrow transplantation.
- Functionally active virus-specific T Cells that target CMV, adenovirus, and EBV can be expanded from naive T-Cell populations in cord blood and will target a range of ...
- LFA-1 regulates CD8+ T Cell activation via T Cell receptor-mediated and LFA-1-mediated Erk1/2 signal pathways.
- LFA-1 affinity regulation is necessary for the activation and proliferation of naive T Cells.
- Phosphatidylinositol 3-kinase mediates bronchioalveolar stem Cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
- Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-Cell skewing.
- Mitochondrial DNA sequence variation in single cells from Leukemia patients.
- Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
- Vaccination for Leukemia.
- Vaccinating transplant recipients.
- Assembly of the kappa preB receptor requires a V kappa-like protein encoded by a germline transcript.
- Functional assessment and specific depletion of alloreactive human T Cells using flow cytometry.
- Immunity to chronic myelogenous Leukemia.
- Immune-induced cytopenia: bone marrow failure syndrome.
- CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host Disease after HLA-identical stem cell transplantation in humans.
- Vaccines in Leukemia.
- Selective depletion of donor alloreactive T Cells without loss of antiviral or antileukemic responses.
- Chronic myelogenous Leukemia shapes host immunity by selective deletion of high-avidity Leukemia-specific T cells.
- Immunotherapy of hematologic malignancy.
- Loss of T-lymphocyte clonal dominance in patients with Myelodysplastic syndrome responsive to immunosuppression.
- Cytomegalovirus reactivation following allogeneic stem Cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T Cells.
- Overexpressed differentiation antigens as targets of graft-versus-Leukemia reactions.
- Antithymocyte globulin for treatment of the bone marrow failure associated with Myelodysplastic syndromes.
- A human Mix-like homeobox gene MIXL shows functional similarity to Xenopus Mix.1.
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy.
- Ex vivo expanded umbilical cord blood T Cells maintain naive phenotype and TCR diversity.
- Immune escape from a graft-versus-Leukemia effect may play a role in the relapse of myeloid Leukemias following allogeneic bone marrow transplantation.
- Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid Leukemia cells: implications for separating graft-versus-Leukemia effect f...
- CD34+ Cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.
- Targeted T-cell therapy for human Leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid Leukemia cells.
- Interaction of natural killer Cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer Cell-mediated cytolysis by bref...
- Alloreactive CD4+ T lymphocytes can exert cytotoxicity to Chronic myeloid leukaemia cells processing and presenting exogenous antigen.
- Specific depletion of alloreactive T Cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions.
- T cell-depleted bone marrow transplantation and delayed T cell add-back to control Acute GVHD and conserve a graft-versus-leukemia effect.
- T Cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ Cell con...
- Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy.
- A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method.
- Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid Leukemia.
- Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor Cells?
- High-dose ifosfamide and etoposide with filgrastim for stem Cell mobilization in patients with advanced ovarian cancer.
- Myelodysplastic syndrome and aplastic Anemia: distinct entities or diseases linked by a common pathophysiology?
- Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.
- High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem Cell transplant recipients.
- Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant Lymphoma.
- Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell Lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
- Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor...
- Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
- Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple Myeloma.
- Immune therapy of AML.
- Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
- Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
- Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.
- HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic Anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
- Immune therapy of chronic myelogenous Leukemia.
- Prognostic factors for outcomes of patients with refractory or relapsed Acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell t...
- T-cell large granular lymphocyte Leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marke...
- HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative Disorders.
- In vivo expansion of LMP 1- and 2-specific T-Cells in a patient who received donor-derived EBV-specific T-Cells after allogeneic stem Cell transplantation.
- Understanding and enhancing the graft-versus-Leukemia effect after hematopoietic stem cell transplantation.
- Cyclic neutropenia associated with T Cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE.
- High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active Disease.
- Risk factors associated with late cytomegalovirus reactivation after allogeneic stem Cell transplantation for hematological malignancies.
- Hookworm infection of sigmoid colon masquerading as graft-versus-host Disease in an allogeneic stem cell transplant recipient after donor lymphocyte infusion for refra...
- A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse Chronic myelogenous le...
- Haematological response of patients with Myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and a...
- Antithymocyte globulin for patients with Myelodysplastic syndrome.
- Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid Leukemia colony-forming units.
- Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous Leukemia.
- Antigen-specific lymphocyte therapies.
- Leukemia vaccines.
- The basis of T-cell-mediated immunity to chronic myelogenous Leukemia.
Schools
Univ Of Mn Med Sch
Clinical Center At The Nih
UCLA Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Elected Member
Education
-
National Institutes of Health Clinical Center -
UCLA Medical Center -
University of Minnesota Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1477647253 | |
| NPPES Provider LastName | MOLLDREM | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477647253 |
| Last Name Of The Provider | MOLLDREM |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Modupe Idowu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priya Ramshesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Fogelman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelina Cairo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle A. Fanale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naval G. Daver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanam Loghavi, MD |
|
|
Dr. Hans Lee, MD |
|
|
Dr. Rakesh C. Mehra, MD |
|
|
Dr. Kurt Sizer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lance C. Pagliaro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan A. Burger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Chitra Hosing, MB
This Doctor is OpenDoctor Recommended.
|